Zacks Investment Research Downgrades Kamada Ltd. (KMDA) to Sell
Kamada Ltd. (NASDAQ:KMDA) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued to investors on Wednesday.
According to Zacks, “Kamada Ltd. is a biopharmaceutical company. It develops, produces and markets therapeutics based on chromatographic purification technology. The company offers bio-therapeutics for specialty proteins, specific immunoglobulins and other prescription medicines. Kamada Ltd. is headquartered in Ness Ziona, Israel. “
Other analysts also recently issued reports about the company. TheStreet raised Kamada from a “sell” rating to a “hold” rating in a research note on Monday, September 26th. Jefferies Group reaffirmed a “buy” rating and issued a $7.00 target price on shares of Kamada in a research note on Wednesday, August 31st. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $10.00 target price on shares of Kamada in a research note on Saturday, September 3rd.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/08/zacks-investment-research-downgrades-kamada-ltd-kmda-to-sell-2.html
Kamada (NASDAQ:KMDA) traded up 1.90% during mid-day trading on Wednesday, hitting $5.35. The company had a trading volume of 37,775 shares. The company has a 50-day moving average price of $4.85 and a 200 day moving average price of $4.11. Kamada has a 52-week low of $3.26 and a 52-week high of $5.45. The company’s market capitalization is $194.84 million.
Kamada (NASDAQ:KMDA) last posted its quarterly earnings data on Tuesday, August 2nd. The company reported ($0.04) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.04). Kamada had a negative return on equity of 10.59% and a negative net margin of 9.92%. The firm earned $19.10 million during the quarter, compared to the consensus estimate of $18.50 million. On average, analysts forecast that Kamada will post ($0.19) EPS for the current fiscal year.
Several institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its position in Kamada by 19.0% in the second quarter. Vanguard Group Inc. now owns 327,533 shares of the company’s stock worth $1,202,000 after buying an additional 52,195 shares in the last quarter. Migdal Insurance & Financial Holdings Ltd. acquired a new position in Kamada during the second quarter worth $1,701,000. Finally, Renaissance Technologies LLC boosted its position in Kamada by 2.4% in the first quarter. Renaissance Technologies LLC now owns 170,300 shares of the company’s stock worth $652,000 after buying an additional 4,000 shares in the last quarter. Institutional investors and hedge funds own 5.31% of the company’s stock.
Kamada Ltd. is an Israel-based biopharmaceutical company, which develops, produces and markets therapeutics, based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The Company’s product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kamada Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.